Sean O'Farrell, Ph.D.


Five years of experience across academia and industry, with expertise in immunobiology, clinical epidemiology and cell therapy process development and manufacturing.

About Sean

Sean joined Dark Horse Consulting in 2021, after 3.5 years of working in both Research & Development and Process Development teams at GammaDelta Therapeutics. His primary area of expertise includes bridging cell therapy processes from research to CMC, with a focus on the use of DoE and subsequent validation runs.

Sean’s immunology career began in the laboratory of Professor Adrian Hayday, where he undertook his Ph.D. and post-doctoral training. During this time, his primary focus was on understanding the immune mechanism of action of adjuvanted influenza vaccination using both clinical and pre-clinical models.

He joined GammaDelta Therpeutics in 2018, where he began to work in the process development and manufacturing team. To aid the development of a GMP-friendly bioprocesses for γδ T-cells, Sean played a key role in designing and deploying DoE approaches to safeguard product yield and quality. In his most recent role within the Research & Development team, he acted as the primary bridge between R&D and CMC, where he led efforts to ensure process reproducibility and simplification prior to the commencement of CMC work and CMO tech transfer. Sean also brings experience in training staff on end-to-end cell therapy processes, DoE design and execution, and scientific presentation.

In addition to his experience in cell therapy process research and development, Sean has experience in assay development and pre-clinical strategy development as well as providing strategic and operational leadership for a wide range of client engagements.


  • Applied DoE approaches via JMP to improve process yield and quality.
  • Successfully led activities to bridge multiple cell therapy processes from R&D to CMC.
  • Authored master batch records for tech transfer to CMOs.
  • Provided on-site training for CMO manufacturing staff to execute cell production processes.
  • Lead efforts for small scale, semi-automated DoE approaches to improve cell production process understanding.


  • O’Farrell S (2022) Harnessing the power of design of experiments for cell therapy research & process development. Cell & Gene Therapy Insights 2022; 8(11), 1487–1495; DOI: 10.18609/cgti.2022.217.
  • O’Farrell S: γδ T-cell therapy: devising a manufacturing-friendly bioprocess. Cell and Gene Therapy Insights, 2020.
  • Sobolev O, Binda E, O’Farrell S, et al: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nature Immunology, 2016.
  • O’Farrell S, Garmo H, Holmberg L, et al: Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. Journal of Clinical Oncology, 2015.
  • O’Farrell S, Sandström K, Garmo H et al: Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU International, 2015.


Gammadelta Therapeutics Limited, London, UK
Senior Scientist, Research & Development
Senior Scientist, Process Development & Manufacturing
Scientist, Process Development & Manufacturing

King’s College London & The Francis Crick Institute, London, UK
Postdoctoral Research Associate


Kings College London, UK
Ph.D. in Immunology

Kings College London, UK
MRes in Translational Medicine

University College Dublin, Ireland
B.Sc. (Hons) in Pharmacology

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.